Plinabulin

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Multiple Myeloma

Conditions

Multiple Myeloma

Trial Timeline

Dec 21, 2021 → Nov 1, 2026

NCT ID

NCT05130827

About Plinabulin

Plinabulin is a phase 2 stage product being developed by BeyondSpring for Multiple Myeloma. The current trial status is active. This product is registered under clinical trial identifier NCT05130827. Target conditions include Multiple Myeloma.

What happened to similar drugs?

20 of 20 similar drugs in Multiple Myeloma were approved

Approved (20) Terminated (0) Active (0)

✅Mirabegron + PlaceboAstellas PharmaApproved

✅Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + PlaceboAstellas PharmaApproved

✅TeclistamabJohnson & JohnsonApproved

✅BortezomibJohnson & JohnsonApproved

✅DaratumumabJohnson & JohnsonApproved

✅Mavenclad®MerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05130827	Phase 2	Active	Dec 21, 2021	Nov 1, 2026	Multiple Myeloma

Competing Products

20 competing products in Multiple Myeloma

See all competitors

Product	Company	Stage	Hype Score
mRNA-1195	Moderna	Phase 2	0
NEX-20A	Nanexa AB	Phase 1	23
mRNA-2736	Moderna	Phase 1	0
mRNA-2808	Moderna	Phase 2	0
Placebo + Pirtobrutinib	Eli Lilly	Phase 2	27
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide	Eli Lilly	Phase 1/2	32
agenT-797	MiNK Therapeutics	Phase 1	19
Duloxetine Hydrochloride (HCI) + Placebo	Eli Lilly	Phase 3	40
Temferon	Genenta Science	Phase 1/2	14
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)	Celltrion	Phase 3	47
CT-P53 + US-Ocrevus + EU-Ocrevus	Celltrion	Phase 3	47
CS-0777 tablets + CS-0777 tablets + CS-0777 tablets	Daiichi Sankyo	Phase 1	29
ASP7487, Velcade, Dexamethasone	Astellas Pharma	Phase 1/2	24
PHE885	Novartis	Phase 2	27
Mirabegron + Placebo	Astellas Pharma	Approved	43
Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo	Astellas Pharma	Approved	43
Denileukin Diftitox (Ontak)	Eisai	Phase 1	21
Palonosetron	Eisai	Phase 2	35
BIW-8962	Kyowa Kirin	Phase 1	21
KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor)	Kyowa Kirin	Phase 2	35